CN116369521A - A composition with intestinal health promoting effect - Google Patents
A composition with intestinal health promoting effect Download PDFInfo
- Publication number
- CN116369521A CN116369521A CN202310231897.8A CN202310231897A CN116369521A CN 116369521 A CN116369521 A CN 116369521A CN 202310231897 A CN202310231897 A CN 202310231897A CN 116369521 A CN116369521 A CN 116369521A
- Authority
- CN
- China
- Prior art keywords
- sesamin
- attapulgite
- essential oil
- ginger essential
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000007413 intestinal health Effects 0.000 title claims abstract description 18
- 230000001737 promoting effect Effects 0.000 title claims abstract description 17
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 63
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 63
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 63
- 241000234314 Zingiber Species 0.000 claims abstract description 48
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 48
- 235000008397 ginger Nutrition 0.000 claims abstract description 48
- 239000000341 volatile oil Substances 0.000 claims abstract description 47
- 229960000892 attapulgite Drugs 0.000 claims abstract description 41
- 229910052625 palygorskite Inorganic materials 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 12
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 11
- 235000012054 meals Nutrition 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 7
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 7
- 235000002780 gingerol Nutrition 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000003871 intestinal function Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000004064 dysfunction Effects 0.000 abstract description 6
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000002110 toxicologic effect Effects 0.000 abstract description 2
- 231100000027 toxicology Toxicity 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 12
- 241000207961 Sesamum Species 0.000 description 10
- 229940010698 activated attapulgite Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000004927 clay Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WXYIONYJZVWSIJ-UHFFFAOYSA-N acetonitrile;methanol;hydrate Chemical compound O.OC.CC#N WXYIONYJZVWSIJ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a composition with an effect of promoting intestinal health, and belongs to the field of biological medicines. The composition is composed of sesamin powder, ginger essential oil and attapulgite powder, has the functions of improving intestinal dysfunction by the sesamin and ginger essential oil, protecting and repairing intestinal mucosa by the attapulgite, and has the functions of synergism and promotion of intestinal health. Pharmacological tests show that the sesamin powder, ginger essential oil and attapulgite powder composition has the functions of regulating intestinal functions, protecting intestinal mucosa, resisting bacteria and inflammation and promoting intestinal health; the combination of sesamin, ginger essential oil and attapulgite is obviously superior to single use or the combination of the sesamin, ginger essential oil and attapulgite, and has synergistic effect. Toxicological tests have shown that the compositions of the invention are safe to use.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a composition with an effect of promoting intestinal health.
Background
Intestinal function directly affects the digestive absorption of nutrients in food by humans and is important to maintain normal function of other organs of the human body. Diarrhea, gastrointestinal dysfunction, chronic inflammation, immune dysfunction and other intestinal dysfunction can cause pain to patients, and damage intestinal health and human health. At present, most of medicines for preventing and treating diarrhea and other intestinal dysfunction are antidiarrheal medicines, antibacterial and anti-inflammatory medicines, and have the problems of large side effect, easiness in generating drug resistance and the like. In the prior art, a novel oral preparation which is natural in origin, obvious in effect and free from obvious adverse reactions and is used for improving the intestinal functions and promoting the intestinal health is lacked, so that the pain of patients is relieved.
Sesamin is a main functional component in sesame seeds, and belongs to lignans; sesamin has various physiological activity functions of resisting oxidation, reducing blood lipid (serum cholesterol and triglyceride), protecting liver and kidney functions, etc., and can be applied to the fields of medicines and health care functional foods.
Ginger is a traditional health-care product resource with homology of medicine and food, and has multiple functions of invigorating stomach, warming stomach, dispelling cold, eliminating dampness, relaxing tendons, promoting blood circulation, resisting inflammation, resisting bacteria and the like. The ginger essential oil is volatile matters extracted from ginger rhizome, is brown transparent oily liquid, and has the pharmacological effects of activating blood circulation to dissipate blood stasis, resisting bacteria, resisting inflammation and the like; the ginger essential oil contains various functional substances such as gingerol, gingerol and the like, and is widely applied to the fields of food, health-care food, cosmetics and medicines.
Attapulgite is a clay mineral with a layered chain structure of hydrous magnesium aluminum silicate, has unique microstructure and charge property, has various excellent properties such as adsorptivity, colloid property and the like, and is widely applied to the fields of medicine, chemical industry, agriculture and environmental protection.
In the prior art, no report on the use of combination compatibility of sesamin, ginger essential oil and attapulgite for improving intestinal dysfunction and promoting intestinal health is found.
Disclosure of Invention
The invention aims to provide a composition with an effect of promoting intestinal health, which is a composition composed of sesamin powder, ginger essential oil and attapulgite powder, has the functions of improving intestinal dysfunction by the sesamin and the ginger essential oil, and protecting and repairing intestinal mucosa by the attapulgite, and has the effects of promoting intestinal health by synergistic interaction.
The mass ratio of sesamin to ginger essential oil to attapulgite powder is 0.1-2:0.1-2:10.
the sesamin is extracted from sesame seed meal, wherein the sesamin content is more than 50%; the ginger essential oil is extracted from ginger, wherein the gingerol content is more than 20%; the attapulgite powder is prepared by selecting attapulgite clay ore type with attapulgite crystal content of more than 50% and carbonate content of less than 10%, and grinding the attapulgite clay ore to 100-320 meshes. The composition can be processed into oral preparation such as granule, tablet, capsule, soft capsule, etc. by well known process.
Pharmacological tests show that the sesamin powder, ginger essential oil and attapulgite powder composition has the functions of regulating intestinal functions, protecting intestinal mucosa, resisting bacteria and inflammation and promoting intestinal health; the combination of sesamin, ginger essential oil and attapulgite is obviously superior to single use or the combination of the sesamin, ginger essential oil and attapulgite, and has synergistic effect. Toxicological tests have shown that the compositions of the invention are safe to use.
Detailed Description
The invention is further described below with reference to examples.
Example 1
A composition with intestinal health promoting effect comprises sesamin powder extracted from sesame seed cake, ginger essential oil extracted from rhizoma Zingiberis recens, and attapulgite powder, wherein the ratio of the sesamin powder to the ginger essential oil to the attapulgite powder is 1:1:10.
(1) Preparation of sesamin extract
The preparation method of sesamin extract comprises the following steps: grinding sesame seed meal into powder, adding n-hexane with the volume being 2 times of that of the sesame seed meal powder, stirring for 3 hours to degrease, filtering, degreasing for the 2 nd time by adopting the same method, filtering, and air-drying to obtain the degreased sesame seed meal. Adding 93% ethanol water solution into defatted sesame seed meal according to the proportion of adding 8.5ml 93% ethanol water solution into each gram of defatted sesame seed meal, stirring in a water bath at 55 ℃ for 2.5h, filtering, separating the extract and the defatted sesame seed meal, and repeatedly extracting the defatted sesame seed meal once by adopting the same method. Mixing the two extractive solutions, filtering, evaporating part of ethanol from the filtrate on rotary evaporator, concentrating under reduced pressure, and vacuum drying at 60deg.C to obtain sesamin extract with sesamin content of 698.07mg/g. The characters of the product are as follows: light brown powder, odorless, tasteless, hygroscopic, alcohol-soluble, and water-insoluble.
The sesamin content determination method comprises the following steps: HPLC was used. The sesamin standard substance solution is between 20 and 100 mug/ml, the corresponding peak area has obvious linear relation with the sesamin mass concentration, and a standard curve is prepared. Dissolving sesamin extract with chromatographic pure absolute ethanol, and filtering. Column temperature: room temperature; mobile phase: methanol-water (8:2, v/v); the flow rate is 0.8ml/min; sample injection amount: 20 μl; the detection wavelength is 290nm; analysis time: 15min. And (5) carrying out qualitative analysis according to the retention time of the standard sample, and calculating the sesamin content by an external standard method.
(2) Preparation of ginger essential oil
The preparation method of the ginger essential oil comprises the following steps: peeling rhizoma Zingiberis recens, cleaning, slicing, drying, and pulverizing to obtain rhizoma Zingiberis recens powder. Reflux-extracting rhizoma Zingiberis recens powder with 70% ethanol solution for 2 times, adding 70% ethanol solution 10 times of rhizoma Zingiberis recens powder, and extracting for 90min; adding 70% ethanol solution with volume 8 times of that of rhizoma Zingiberis recens powder into the second extraction, extracting for 60min, mixing ethanol extractive solutions, filtering, concentrating the filtrate under reduced pressure, and evaporating ethanol to obtain rhizoma Zingiberis recens essential oil. The characters of the product are as follows: pale yellow oily substance, has pungent taste, is soluble in alcohol, and is insoluble in water. The gingerol content in the ginger essential oil is 246.25mg/g.
The method for measuring the gingerol content comprises the following steps: adopting an HPLC method; dissolving rhizoma Zingiberis recens essential oil with chromatographic pure anhydrous ethanol, and filtering. Column temperature: room temperature; mobile phase: acetonitrile-methanol-water (40:5:55); the flow rate is 0.8ml/min; sample injection amount: 20 μl; the detection wavelength was 280nm. And (5) performing qualitative analysis according to the retention time of the standard sample, and calculating the content of gingerol by an external standard method.
(3) Activation of attapulgite
An attapulgite clay ore type having an attapulgite crystal content of greater than 50% and a carbonate content of less than 10% is selected. The attapulgite powder ground to 200 meshes is taken and added into a beaker filled with hydrochloric acid with the mass percentage concentration of 20%, a plastic film is sealed, and the mixture is magnetically stirred for 10 hours in a water bath at 60 ℃. Then, the supernatant was removed by centrifugation at 10000rpm, and the precipitate was washed with deionized water multiple times to give a supernatant having a neutral pH and a transparent color. Adding the washed precipitate into 10 percent (mass percentage concentration) sodium chloride aqueous solution, and performing ultrasonic treatment to form a suspension system; then magnetically stirring in a water bath at 60 ℃ for 10 hours; centrifuging at 10000rpm, collecting upper layer light gray solid, and drying at 70deg.C in electrothermal constant temperature air drying oven to constant weight to obtain activated attapulgite.
Example 2
In this example, animal experiments were performed using sesamin extract, ginger essential oil and activated attapulgite prepared in example 1 to examine the effects of sesamin extract, ginger essential oil and activated attapulgite in regulating intestinal function, protecting intestinal mucosa, resisting bacteria and inflammation, and promoting intestinal health. The sesamin used in this example was added as a sesamin extract, and the mass of the sesamin extract used was calculated based on the sesamin content of 698.07mg/g in the sesamin extract.
Preparation of E.coli bacterial suspension: inoculating Escherichia coli into LB medium, shake culturing at 37deg.C for 12 hr, centrifuging to obtain bacterial precipitate, washing bacterial precipitate with sterilized normal saline for 2 times, centrifuging, and making into 2×10 with sterilized normal saline 10 The CFU/mL E.coli suspension was stored at 4℃for further use.
Establishing a diarrhea model of an E.coli infected animal: c (C) 57 BL/6J mice were fasted and free-drinking water was performed 12 hours prior to the experiment. Each of whichE.coli liquid is injected into the abdominal cavity of the mice by 0.5mL, and when the mice have obvious diarrhea symptoms, watery stool, listlessness, slow action and other symptoms, the establishment of the diarrhea model of the animals infected by E.coli is successful; each mouse of the control group was intraperitoneally injected with an equal volume of sterilized normal saline.
And (3) test design: SPF class C6 weeks old 57 BL/6J mice 108 (male and female halves). All mice were acclimatized in a constant temperature and humidity SFP grade animal house for 3 days, controlled to 12h light/dark, with an ambient temperature of 25%, during which time the mice were free to eat and feed. After the adaptation, the mice were divided into 9 groups (12 groups each, each half of male and female) by a random method, which were respectively a normal control group, a model control group, and sesamin (ZMS, 60 mg. Kg) -1 ·d -1 ) Group ginger essential oil (GEO, 60 mg.kg) -1 ·d -1 ) Group, activated attapulgite (PGS, 60 mg.kg) -1 ·d -1 ) Group ZMS+GEO (30+30mg.kg) -1 ·d -1 ) Group ZMS+PGS (30+30mg.kg) -1 ·d -1 ) Group GEO+PGS (30+30mg.kg) -1 ·d -1 ) Group ZMS+GEO+PGS (20+20+20mg.kg) -1 ·d -1 ) A group. The administration was continued for 6 days.
The detection indexes comprise: the feed was weighed once a day and replaced and the average mouse feed intake was calculated. Mice body weight was recorded daily. The mice were observed for mental state, gastrointestinal tract response, motor and reactive capacity, etc. during the experiment. Diarrhea index: placing the mice into a squirrel cage paved with filter paper, and observing diarrhea condition of the mice; the diarrhea rate was calculated.
The results of the animal experiments are shown in tables 1-3 below.
TABLE 1 influence on mouse body weight
Note that: in Table 1, when a plurality of drugs are administered in a certain group, the numbers in the corresponding dose columns are added, wherein the positions of the numbers correspond to the drugs in the dose columns, for example ZMS+GEO group, and "30+30" in the dose columns indicates that sesamin 30 mg.kg.d. is administered -1 He Jiang (He Jiang)30 mg/kg/d essential oil -1 The same applies below; in comparison with the normal control group' * "P < 0.05" ** "means P < 0.01; in comparison with the model control group' # "P < 0.05" ## "means P < 0.01.
TABLE 2 influence on the food intake of mice
Note that: in Table 2, "compared with the normal control group" * "P < 0.05" ** "means P < 0.01; in comparison with the model control group' # "P < 0.05" ## "means P < 0.01.
TABLE 3 effect on diarrhea rate in mice
The results show that compared with the normal control group, the weight and the feeding amount of the mice in the model control group are obviously reduced, and the diarrhea rate is obviously increased. Compared with a model control group, the sesamin (ZMS), ginger Essential Oil (GEO) and attapulgite (PGS) intervention can obviously restore the weight and the food intake of diarrhea mice, reduce the diarrhea rate and promote the rehabilitation of the mice. The sesamin (ZMS), ginger Essential Oil (GEO) and attapulgite (PGS) have the effects of regulating intestinal functions, resisting bacteria and inflammation, protecting intestinal mucosa and promoting intestinal health; the combination of sesamin, ginger essential oil and attapulgite is obviously better than single use or the combination of the sesamin, ginger essential oil and attapulgite, and has synergistic effect. The above results show that the combination of sesamin, ginger essential oil and attapulgite has the effect of synergistically enhancing the drug effect.
The acute toxicity test result shows that the maximum dosage (MTD) of sesamin (ZMS) +ginger essential oil (GEO) +attapulgite (PGS) for gastric lavage of the mice is 22.9g/kg, which is equivalent to 70 times of the effective dosage; the animals did not show any adverse reactions. The product of the invention is safe and has almost no toxic or side effect.
Example 3
In this example, sesamin extract, ginger essential oil and activated attapulgite prepared in example 1 were used to prepare various preparations of drugs for promoting intestinal health. The sesamin used in this example was added as a sesamin extract, and the mass of the sesamin extract used was calculated based on the sesamin content of 698.07mg/g in the sesamin extract.
A tablet contains sesamin extract, ginger essential oil and activated attapulgite, each tablet contains 60mg sesamin, 120mg ginger essential oil and 600mg attapulgite. Mixing sesamin, ginger essential oil and attapulgite uniformly, and preparing tablets according to a conventional method.
A powder containing sesamin extract, ginger essential oil and activated attapulgite is provided, wherein each bag contains 120mg sesamin, 60mg ginger essential oil and 600mg attapulgite. Mixing sesamin, ginger essential oil and attapulgite uniformly, and preparing powder according to a conventional method.
A capsule contains sesamin extract, ginger essential oil and activated attapulgite, and each capsule contains 60mg sesamin, 30mg ginger essential oil and 600mg attapulgite. Mixing sesamin, ginger essential oil and attapulgite uniformly, and preparing capsules according to a conventional method.
The total mass of sesamin, ginger essential oil and attapulgite is about 700mg in terms of the effective part composition, and the oral dosage is used for regulating and improving intestinal functions and promoting intestinal health (such as intestinal dysfunction caused by chronic intestinal inflammation, functional dyspepsia, irritable bowel syndrome and the like), and the powder administration method is 2 times per day, 1 bag per time and warm boiled water for administration; the tablet is administered by 1-2 tablets each time, 2 times daily; the capsule is administered by 1-2 capsules each time, 2 times daily. 1 month is a treatment course.
Claims (6)
1. The composition with the effect of promoting intestinal health is characterized by comprising sesamin, ginger essential oil and attapulgite, wherein the mass ratio of sesamin to ginger essential oil to attapulgite is 0.1-2:0.1-2: 10-20.
2. The composition of claim 1, wherein the sesamin is extracted from sesame seed meal, wherein the sesamin content is greater than 50%.
3. Composition according to claim 1 or 2, wherein the ginger essential oil is extracted from ginger with a gingerol content of more than 20%.
4. A composition according to claim 3, wherein the attapulgite has a rod crystal content of greater than 50% and a carbonate content of less than 10%.
5. The composition of claim 4, wherein the attapulgite is ground to a powder of 100-320 mesh.
6. The composition of claim 5, wherein sesamin, ginger essential oil and attapulgite are mixed uniformly, and mixed with excipient to make powder, granule, tablet or capsule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023100247037 | 2023-01-06 | ||
| CN202310024703 | 2023-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116369521A true CN116369521A (en) | 2023-07-04 |
Family
ID=86962523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310231897.8A Pending CN116369521A (en) | 2023-01-06 | 2023-03-07 | A composition with intestinal health promoting effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116369521A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090054443A1 (en) * | 2006-03-15 | 2009-02-26 | Suntory Limited | Compositions containing riboflavin and sesamin-class compounds |
| JP2009279011A (en) * | 2009-09-02 | 2009-12-03 | Tsujido Chemical Corp | Food composition |
| JP2010024240A (en) * | 2009-10-30 | 2010-02-04 | Tsujido Chemical Corp | Clathrate and method for producing the same |
| CN106110276A (en) * | 2016-08-24 | 2016-11-16 | 南京财经大学 | A kind of have the complex improving functional gastrointestinal disorder effect |
-
2023
- 2023-03-07 CN CN202310231897.8A patent/CN116369521A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090054443A1 (en) * | 2006-03-15 | 2009-02-26 | Suntory Limited | Compositions containing riboflavin and sesamin-class compounds |
| JP2009279011A (en) * | 2009-09-02 | 2009-12-03 | Tsujido Chemical Corp | Food composition |
| JP2010024240A (en) * | 2009-10-30 | 2010-02-04 | Tsujido Chemical Corp | Clathrate and method for producing the same |
| CN106110276A (en) * | 2016-08-24 | 2016-11-16 | 南京财经大学 | A kind of have the complex improving functional gastrointestinal disorder effect |
Non-Patent Citations (1)
| Title |
|---|
| 刘苗苗 等: ""果蔬与肠道菌群互作及其健康功效研究进展"", 《中国食品学报》, vol. 22, no. 4, 30 April 2022 (2022-04-30), pages 387 - 407 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103127215B (en) | Extract of joss-stick having anti-arthritic activity | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| EP1354518A1 (en) | Kernel oil from plant kernel, process for extracting same, pharmaceutical composition and use thereof | |
| EP2040726A1 (en) | Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases | |
| CN101332256B (en) | Traditional Chinese medicine composition for infectious bursal disease and preparation method thereof | |
| CN108324921B (en) | A pharmaceutical composition with cyst removing and gastric mucosa protecting effects, and its preparation method | |
| KR101439405B1 (en) | Composition for preventing or treating renal disease | |
| CN111714519B (en) | Application and composition of organic solvent extract of sea cockroach | |
| CN104857436B (en) | Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application | |
| CN103191175B (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN116369521A (en) | A composition with intestinal health promoting effect | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN111840448B (en) | Preparation method and application of anti-chapping compound traditional Chinese medicine liposome | |
| KR100506950B1 (en) | Immune stimulative constituents of ginseng saponins | |
| CN110123859B (en) | Chrysanthemum leaf extract for preventing and treating liver injury and application thereof | |
| JP4167849B2 (en) | Fruit oil extracted from plant fruit, its extraction method, pharmaceutical composition and use thereof | |
| CN1089242C (en) | Method for extracting active component of sea cockroach | |
| RU2452242C1 (en) | Biologically active food additive production method | |
| CN101185668A (en) | Novel preparation for preventing and controlling acquired immuno-deficiency syndrome and protecting liver and detoxication | |
| CN1188000A (en) | Intestinal microecological preparation | |
| CN105125639A (en) | Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle | |
| CN1424052A (en) | Medicine for treating chronic hepatitis B | |
| JPH09187248A (en) | Antiallergic food | |
| US6582733B1 (en) | Composition for the treatment of hepatitis including HCV | |
| KR20060058729A (en) | Neutralizing agent for cavitating toxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |